Internal Medicine

The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.

Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.

Analysis of UK Biobank data combined with a meta-analysis of published literature provides clinicians with an overview of the relationship between type 2 diabetes and accelerated neurocognitive decline.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The treatment recently became the first ever FDA-approved medication for EoE.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

The lead author of treatment recommendations weighs in on their current use and future research.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.

New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.

The data presented at DDW show similar safety and efficacy for the 2 treatments.

There remains a need for longer-term observational studies comparing the 2 treatments.

A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.

Sarcoidosis expert Dr. Wonder Drake got into the field after diagnosing a patient with the disease early in her career. In this interview she explains the best way to approach a suspected case of sarcoidosis.

The bioactive triterpenoid saponin was associated with edema in treated patients.

Christian Lillis of the Peggy Lillis Foundation for C. Diff Education & Advocacy discusses the need for greater industry-organization support and drug development.

In this interview, Dr. Wonder Drake shares physician resources and explains the unique presentation of sarcoidosis and how it varies by region.

The first controlled trial of the combination therapy shows its benefit in 6-week depressive symptom improvement versus lone bupropion.

A South Korea in-hospital assessment found that approximately half of all ordered CDI tests did not meet recommendation standards.

Investigators in a new multicenter study observed poor vaccine-induced serological responses in patients treated with infliximab or tofacitinib.

Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.

New data suggest prediction of SARS-CoV-2 and bacterial co-infection or superinfection could be provided for hospitalized patients.

A Massachusetts General Hospital investigator explains how the innovative DCD practice addresses both waitlist issues and transplant center's capabilities.

Dr. Gerald Smetana encourages PCPs to familiarize themselves with the outpatient drug options for managing COVID-19 because of the limited treatment window for administration.

Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.

Patients who demonstrated high trough concentrations early on in treatment were more likely to achieve remission by weeks 14 or 52.